Top

Published in:

01-02-2012 | Review

Primary aldosteronism: from bench to bedside

Author: Norlela Sukor

Published in: Endocrine | Issue 1/2012

Abstract

Primary aldosteronism is now thought to be the commonest potentially curable and specifically treatable form of hypertension. The detection of primary aldosteronism is of utmost importance not only because it provides an opportunity for a targeted treatment, but also because it has been demonstrated that patients with primary aldosteronism are more prone to cardiovascular events and target organ damage than essential hypertensives. Normalization of blood pressure and hypokalemia should not be the only goal of treatment. Normalization of circulating aldosterone or mineralocorticoid blockade is necessary to prevent aldosterone-induced tissue damage that occurs independent of blood pressure. This review will focus on the current understanding and comprehensive management review of primary aldosteronism, highlighting the new evidence that has become recently available.

S.A. Simpson, J.F. Tait, A. Wettstein, R. Neher, J. Von Euw, O. Schindler, T. Reichstein, Constitution of aldosterone, a new mineralocorticoid. Experientia 10, 132–133 (1954)PubMedCrossRef

J.W. Conn, The evolution of primary aldosteronism: 1954–1967. Harvey Lect. 62, 257–291 (1966)PubMed

P. Milliez, X. Girerd, P.F. Plouin, J. Blacher, M.E. Safar, J.J. Mourad, Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45, 1243–1248 (2005)PubMedCrossRef

M. Stowasser, J. Sharman, R. Leano, R.D. Gordon, G. Ward, D. Cowley, T.H. Marwick, Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J. Clin. Endocrinol. Metab. 90, 5070–5076 (2005)PubMedCrossRef

C. Catena, G. Colussi, E. Nadalini, A. Chiuch, S. Baroselli, R. Lapenna, L.A. Sechi, Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch. Intern. Med. 168, 80–85 (2008)PubMedCrossRef

D.J. Sutherland, J.L. Ruse, J.C. Laidlaw, Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can. Med. Assoc. J. 95, 1109–1119 (1966)PubMed

R.P. Lifton, R.G. Dluhy, M. Powers, G.M. Rich, S. Cook, S. Ulick, J.M. Lalouel, A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355, 262–265 (1992)PubMedCrossRef

J.R. Jonsson, S.A. Klemm, T.J. Tunny, M. Stowasser, R.D. Gordon, A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem. Biophys. Res. Commun. 207, 565–571 (1995)PubMedCrossRef

R.D. Gordon, M. Stowasser, T.J. Tunny, S.A. Klemm, W.L. Finn, A.L. Krek, Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clin. Exp. Pharmacol. Physiol. 18, 283–286 (1991)PubMedCrossRef

10.

Jeskey Y, So A, Gordon RD, Duffy D, Kelemen L, Bulmer B, Stowasser M, Genetic Basis of familial hyperaldosteronism type II: further evidence of linkage at chromosome 7p22. In: Hypertension. 28th Annual Scientific Meeting of the High Blood Pressure Research Council of Australia, Brisbane, Australia, 49, 1477 (2007)

11.

N. Sukor, P. Mulatero, R.D. Gordon, A. So, D. Duffy, C. Bertello, L. Kelemen, Y. Jeske, F. Veglio, M. Stowasser, Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. J. Hypertens. 26, 1577–1582 (2008)PubMedCrossRef

12.

Y.W. Jeske, A. So, L. Kelemen, N. Sukor, C. Willys, B. Bulmer, R.D. Gordon, D. Duffy, M. Stowasser, Examination of chromosome 7p22 candidate genes RBaK, PMS2 and GNA12 in familial hyperaldosteronism type II. Clin. Exp. Pharmacol. Physiol. 35, 380–385 (2008)PubMedCrossRef

13.

So A. Jeske YW, Kelemen L, Bulmer B, Gordon RD, Duffy D, Stowasser M, Examination of candidate genes at chromosome 7p22 in familial hyperaldosteronism type II. Hypertension, 49, 1469 (2007)

14.

D.S. Geller, J. Zhang, M.V. Wisgerhof, C. Shackleton, M. Kashgarian, R.P. Lifton, A novel form of human Mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J. Clin. Endocrinol. Metab. 93, 3117–3123 (2008)PubMedCrossRef

15.

M. Choi, U.I. Scholl, P. Yue, P. Bjorklund, B. Zhao, C. Nelson-Williams, W. Ji, Y. Cho, A. Patel, C.J. Men, E. Lolis, M.V. Wisgerhof, D.S. Geller, S. Mane, P. Hellman, G. Westin, G. Akerstrom, W. Wang, T. Carling, R.P. Lifton, K⁺ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331, 768–772 (2011)PubMedCrossRef

16.

R.D. Gordon, M. Stowasser, T.J. Tunny, S.A. Klemm, J.C. Rutherford, High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin. Exp. Pharmacol. Physiol. 21, 315–318 (1994)PubMedCrossRef

17.

P. Mulatero, M. Stowasser, K.C. Loh, C.E. Fardella, R.D. Gordon, L. Mosso, C.E. Gomez-Sanchez, F. Veglio, W. F. Young Jr, Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J. Clin. Endocrinol. Metab. 89, 1045–1050 (2004)PubMedCrossRef

18.

G.P. Rossi, G. Bernini, C. Caliumi, G. Desideri, B. Fabris, C. Ferri, C. Ganzaroli, G. Giacchetti, C. Letizia, M. Maccario, F. Mallamaci, M. Mannelli, M.J. Mattarello, A. Moretti, G. Palumbo, G. Parenti, E. Porteri, A. Semplicini, D. Rizzoni, E. Rossi, M. Boscaro, A.C. Pessina, F. Mantero, A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J. Am. Coll. Cardiol. 48, 2293–2300 (2006)PubMedCrossRef

19.

L. Mosso, C. Carvajal, A. Gonzalez, A. Barraza, F. Avila, J. Montero, A. Huete, A. Gederlini, C.E. Fardella, Primary aldosteronism and hypertensive disease. Hypertension 42, 161–165 (2003)PubMedCrossRef

20.

M.K. Nishizaka, M. Pratt-Ubunama, M.A. Zaman, S. Cofield, D.A. Calhoun, Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am. J. Hypertens. 18, 805–812 (2005)PubMedCrossRef

21.

G.E. Umpierrez, P. Cantey, D. Smiley, A. Palacio, D. Temponi, K. Luster, A. Chapman, Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care 30, 1699–1703 (2007)PubMedCrossRef

22.

G. Bernini, A. Moretti, G. Argenio, A. Salvetti, Primary aldosteronism in normokalemic patients with adrenal incidentalomas. Eur. J. Endocrinol. 146, 523–529 (2002)PubMedCrossRef

23.

D.A. Calhoun, M.K. Nishizaka, M.A. Zaman, R.B. Thakkar, P. Weissmann, Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40, 892–896 (2002)PubMedCrossRef

24.

A. Di Murro, L. Petramala, D. Cotesta, L. Zinnamosca, E. Crescenzi, C. Marinelli, M. Saponara, C. Letizia, Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 11, 165–172 (2010)PubMedCrossRef

25.

R.D. Gordon, M. Stowasser, Primary aldosteronism: the case for screening. Nat Clin Pract Nephrol 3, 582–583 (2007)PubMedCrossRef

26.

D.A. Calhoun, Is there an unrecognized epidemic of primary aldosteronism? (Pro). Hypertension 50, 447–453 (2007). discussion 447–53PubMedCrossRef

27.

N.M. Kaplan, Is there an unrecognized epidemic of primary aldosteronism? (Con). Hypertension 50, 454–458 (2007). discussion 454–8PubMedCrossRef

28.

J.W. Funder, R.M. Carey, C. Fardella, C.E. Gomez-Sanchez, F. Mantero, M. Stowasser, W. F. Young Jr., V.M. Montori, Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 3266–3281 (2008)PubMedCrossRef

29.

M. Stowasser, R.D. Gordon, J.C. Rutherford, N.Z. Nikwan, N. Daunt, G.J. Slater, Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2, 156–169 (2001)PubMedCrossRef

30.

R.D. Gordon, Primary aldosteronism. J. Endocrinol. Invest. 18, 495–511 (1995)PubMed

31.

P. Mulatero, F. Rabbia, A. Milan, C. Paglieri, F. Morello, L. Chiandussi, F. Veglio, Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 40, 897–902 (2002)PubMedCrossRef

32.

M. Stowasser, R.D. Gordon, Primary aldosteronism—careful investigation is essential and rewarding. Mol. Cell. Endocrinol. 217, 33–39 (2004)PubMedCrossRef

33.

D.J. Campbell, J. Nussberger, M. Stowasser, A.H. Danser, A. Morganti, E. Frandsen, J. Menard, Activity assays and immunoassays for plasma Renin and prorenin: information provided and precautions necessary for accurate measurement. Clin. Chem. 55, 867–877 (2009)PubMedCrossRef

34.

A.H. Ahmed, R.D. Gordon, P.J. Taylor, G. Ward, E. Pimenta, M. Stowasser, Effect of contraceptives on aldosterone/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J J Clin Endocrinol Metab 96, 1797–1804 (2011)CrossRef

35.

F.H. Derkx, C. Steunkel, M.P. Schalekamp, W. Visser, I.H. Huisveld, M.A. Schalekamp, Immunoreactive renin, prorenin, and enzymatically active renin in plasma during pregnancy and in women taking oral contraceptives. J. Clin. Endocrinol. Metab. 63, 1008–1015 (1986)PubMedCrossRef

36.

S.Z. Goldhaber, C.H. Hennekens, R.F. Spark, D.A. Evans, B. Rosner, J.O. Taylor, E.H. Kass, Plasma renin substrate, renin activity, and aldosterone levels in a sample of oral contraceptive users from a community survey. Am. Heart J. 107, 119–122 (1984)PubMedCrossRef

37.

A.H. Ahmed, M. Calvird, R.D. Gordon, P.J. Taylor, G. Ward, E. Pimenta, R. Young, M. Stowasser, Effects of two selective serotonin reuptake inhibitor antidepressants, sertraline and escitalopram, on aldosterone/renin ratio in normotensive depressed male patients. J. Clin. Endocrinol. Metab. 96, 1039–1045 (2011)PubMedCrossRef

38.

M. Stowasser, R.D. Gordon, Primary aldosteronism. Best Pract Res Clin Endocrinol Metab 17, 591–605 (2003)PubMedCrossRef

39.

E. Letavernier, S. Peyrard, L. Amar, F. Zinzindohoue, B. Fiquet, P.F. Plouin, Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J. Hypertens. 26, 1816–1823 (2008)PubMedCrossRef

40.

K.C. Loh, E.S. Koay, M.C. Khaw, S.C. Emmanuel, W. F. Young Jr, Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J. Clin. Endocrinol. Metab. 85, 2854–2859 (2000)PubMedCrossRef

41.

G.P. Rossi, T.M. Seccia, A.C. Pessina, Primary aldosteronism—part I: prevalence, screening, and selection of cases for adrenal vein sampling. J Nephrol 21, 447–454 (2008)PubMed

42.

W.F.J. Young, Primary aldosteronism: update on diagnosis and treatment. Endocrinologist 7, 213–221 (1997)CrossRef

43.

P. Mulatero, C. Bertello, C. Garrone, D. Rossato, G. Mengozzi, A. Verhovez, F. Fallo, F. Veglio, Captopril test can give misleading results in patients with suspect primary aldosteronism. Hypertension 50, e26–e27 (2007)PubMedCrossRef

44.

G.P. Rossi, A. Belfiore, G. Bernini, G. Desideri, B. Fabris, C. Ferri, G. Giacchetti, C. Letizia, M. Maccario, F. Mallamaci, M. Mannelli, G. Palumbo, D. Rizzoni, E. Rossi, E. Agabiti-Rosei, A.C. Pessina, F. Mantero, Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension 50, 424–431 (2007)PubMedCrossRef

45.

M. Stowasser, Update in primary aldosteronism. J. Clin. Endocrinol. Metab. 94, 3623–3630 (2009)PubMedCrossRef

46.

F.E. Nwariaku, B.S. Miller, R. Auchus, S. Holt, L. Watumull, B. Dolmatch, S. Nesbitt, W. Vongpatanasin, R. Victor, F. Wians, E. Livingston, W. H. Snyder 3rd, Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch. Surg. 141, 497–502 (2006). discussion 502–3PubMedCrossRef

47.

W.F. Young, A.W. Stanson, G.B. Thompson, C.S. Grant, D.R. Farley, J.A. van Heerden, Role for adrenal venous sampling in primary aldosteronism. Surgery 136, 1227–1235 (2004)PubMedCrossRef

48.

T. Nishikawa, M. Omura, Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed. Pharmacother. 54(Suppl 1), 83s–85s (2000)PubMed

49.

M. Omura, H. Sasano, T. Fujiwara, K. Yamaguchi, T. Nishikawa, Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. Metabolism 51, 350–355 (2002)PubMedCrossRef

50.

M.J. Kempers, J.W. Lenders, L. van Outheusden, G.J. van der Wilt, L.J. Schultze Kool, A.R. Hermus, J. Deinum, Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann. Intern. Med. 151, 329–337 (2009)PubMed

51.

G.P. Rossi, A. Sacchetto, M. Chiesura-Corona, R. De Toni, M. Gallina, G.P. Feltrin, A.C. Pessina, Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J. Clin. Endocrinol. Metab. 86, 1083–1090 (2001)PubMedCrossRef

52.

C. Plank, F. Wolf, H. Langenberger, C. Loewe, M. Schoder and J. Lammer, Adrenal venous sampling using Dyna-CT-A practical guide. Eur J Radiol (2011)

53.

G.P. Rossi, C. Ganzaroli, D. Miotto, R. De Toni, G. Palumbo, G.P. Feltrin, F. Mantero, A.C. Pessina, Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of aldosterone oversecretion in primary aldosteronism patients. J. Hypertens. 24, 371–379 (2006)PubMedCrossRef

54.

T.M. Seccia, D. Miotto, R. De Toni, G. Pitter, F. Mantero, A.C. Pessina, G.P. Rossi, Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different protocols. Hypertension 53, 761–766 (2009)PubMedCrossRef

55.

J. Hennings, A. Sundin, A. Hagg, P. Hellman, 11C-metomidate positron emission tomography after dexamethasone suppression for detection of small adrenocortical adenomas in primary aldosteronism. Langenbecks Arch Surg 395, 963–967 (2010)PubMedCrossRef

56.

W. F. Young Jr, Minireview: primary aldosteronism—changing concepts in diagnosis and treatment. Endocrinology 144, 2208–2213 (2003)PubMedCrossRef

57.

L.A. Sechi, G. Colussi, A. Di Fabio, C. Catena, Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am. J. Hypertens. 23, 1253–1260 (2010)PubMedCrossRef

58.

A.H. Ahmed, R.D. Gordon, N. Sukor, E. Pimenta, M. Stowasser, Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J. Clin. Endocrinol. Metab. 96, 2904–2911 (2011)PubMedCrossRef

59.

N. Sukor, C. Kogovsek, R.D. Gordon, D. Robson, M. Stowasser, Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J. Clin. Endocrinol. Metab. 95, 1360–1364 (2010)PubMedCrossRef

60.

N. Sonino, E. Tomba, M.L. Genesia, C. Bertello, P. Mulatero, F. Veglio, G.A. Fava, F. Fallo, Psychological assessment of primary aldosteronism: a controlled study. J. Clin. Endocrinol. Metab. 96, E878–E883 (2011)PubMedCrossRef

61.

J.C. Rutherford, W.L. Taylor, M. Stowasser, R.D. Gordon, Success of surgery for primary aldosteronism judged by residual autonomous aldosterone production. World J. Surg. 22, 1243–1245 (1998)PubMedCrossRef

62.

M. Stowasser, S.A. Klemm, T.J. Tunny, W.J. Storie, J.C. Rutherford, R.D. Gordon, Response to unilateral adrenalectomy for aldosterone-producing adenoma: effect of potassium levels and angiotensin responsiveness. Clin. Exp. Pharmacol. Physiol. 21, 319–322 (1994)PubMedCrossRef

63.

N.E. Jacobsen, J.B. Campbell, M.G. Hobart, Laparoscopic versus open adrenalectomy for surgical adrenal disease. Can J Urol 10, 1995–1999 (2003)PubMed

64.

H. Rossi, A. Kim, R.A. Prinz, Primary hyperaldosteronism in the era of laparoscopic adrenalectomy. Am. Surg. 68, 253–256 (2002). discussion 256–7PubMed

65.

J.C. Rutherford, M. Stowasser, T.J. Tunny, S.A. Klemm, R.D. Gordon, Laparoscopic adrenalectomy. World J. Surg. 20, 758–760 (1996). discussion 761PubMedCrossRef

66.

J.J. Brown, D.L. Davies, J.B. Ferriss, R. Fraser, E. Haywood, A.F. Lever, J.I. Robertson, Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. Br. Med. J. 2, 729–734 (1972)PubMedCrossRef

67.

J.Y. Pagny, G. Chatellier, J.M. Duclos, P.F. Plouin, P. Corvol, J. Menard, Results of the surgical treatment of Conn’s adenomas. Archives des Maladies du Coeur et des Vaisseaux 80, 995–998 (1987)PubMed

68.

C.A. Proye, E.A. Mulliez, B.M. Carnaille, M. Lecomte-Houcke, M. Decoulx, J.L. Wemeau, J. Lefebvre, A. Racadot, O. Ernst, D. Huglo, A. Carre, Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Surgery 124, 1128–1133 (1998)PubMedCrossRef

69.

Y. Horita, T. Inenaga, H. Nakahama, H. Ishibashi-Ueda, Y. Kawano, S. Nakamura, T. Horio, N. Okuda, M. Ando, S. Takishita, Cause of residual hypertension after adrenalectomy in patients with primary aldosteronism. Am. J. Kidney Dis. 37, 884–889 (2001)PubMedCrossRef

70.

Y. Fukudome, K. Fujii, H. Arima, Y. Ohya, T. Tsuchihashi, I. Abe, M. Fujishima, Discriminating factors for recurrent hypertension in patients with primary aldosteronism after adrenalectomy. Hypertens. Res. 25, 11–18 (2002)PubMedCrossRef

71.

T. Obara, Y. Ito, T. Okamoto, Y. Kanaji, T. Yamashita, M. Aiba, Y. Fujimoto, Risk factors associated with postoperative persistent hypertension in patients with primary aldosteronism. Surgery 112, 987–993 (1992)PubMed

72.

G. Favia, F. Lumachi, V. Scarpa, D.F. D’Amico, Adrenalectomy in primary aldosteronism: a long-term follow-up study in 52 patients. World J. Surg. 16, 680–683 (1992). discussion 683–4PubMedCrossRef

73.

P. Sapienza, A. Cavallaro, Persistent hypertension after removal of adrenal tumours. Eur. J. Surg. 165, 187–192 (1999)PubMedCrossRef

74.

C.Y. Lo, P.C. Tam, A.W. Kung, K.S. Lam, J. Wong, Primary aldosteronism. Results of surgical treatment. Ann. Surg. 224, 125–130 (1996)PubMedCrossRef

75.

R.J. Weigel, S.A. Wells, J.C. Gunnells, G.S. Leight, Surgical treatment of primary hyperaldosteronism. Ann. Surg. 219, 347–352 (1994)PubMedCrossRef

76.

A.M. Sawka, W.F. Young, G.B. Thompson, C.S. Grant, D.R. Farley, C. Leibson, J.A. van Heerden, Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann. Intern. Med. 135, 258–261 (2001)PubMed

77.

X. Jeunemaitre, G. Chatellier, C. Kreft-Jais, A. Charru, C. DeVries, P.F. Plouin, P. Corvol, J. Menard, Efficacy and tolerance of spironolactone in essential hypertension. Am. J. Cardiol. 60, 820–825 (1987)PubMedCrossRef

78.

M.H. Weinberger, B. Roniker, S.L. Krause, R.J. Weiss, Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. 15, 709–716 (2002)PubMedCrossRef

79.

M. de Gasparo, U. Joss, H.P. Ramjoue, S.E. Whitebread, H. Haenni, L. Schenkel, C. Kraehenbuehl, M. Biollaz, J. Grob, J. Schmidlin et al., Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J. Pharmacol. Exp. Ther. 240, 650–656 (1987)PubMed

80.

A. Karagiannis, K. Tziomalos, A. Papageorgiou, A.I. Kakafika, E.D. Pagourelias, P. Anagnostis, V.G. Athyros, D.P. Mikhailidis, Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 9, 509–515 (2008)PubMedCrossRef

81.

H.K. Parthasarathy, J. Menard, W.B. White, W. F. Young Jr., G.H. Williams, B. Williams, L.M. Ruilope, G.T. McInnes, J.M. Connell, T.M. MacDonald, A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J. Hypertens. 29, 980–990 (2011)PubMedCrossRef

82.

G.T. Griffing, A.G. Cole, S.A. Aurecchia, B.H. Sindler, P. Komanicky, J.C. Melby, Amiloride in primary hyperaldosteronism. Clin. Pharmacol. Ther. 31, 56–61 (1982)PubMedCrossRef

83.

G.T. Griffing, J.C. Melby, The therapeutic use of a new potassium-sparing diuretic, amiloride, and a converting enzyme inhibitor, MK-421, in preventing hypokalemia associated with primary and secondary hyperaldosteronism. Clin Exp Hypertens A Theory Practice 5, 779–801 (1983)CrossRef

84.

F. Mantero, F. Fallo, G. Opocher, D. Armanini, M. Boscaro, C. Scaroni, Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism. Clin Sci (London) 61(Suppl 7), 289s–293s (1981)

85.

S. Zacharieva, I. Atanassova, E. Natchev, M. Orbetzova, D. Tzingilev, Effect of short-term losartan treatment in patients with primary aldosteronism and essential hypertension. Methods Find. Exp. Clin. Pharmacol. 23, 153–156 (2001)PubMedCrossRef

86.

M.J. Brown, R.V. Hopper, Calcium-channel blockade can mask the diagnosis of Conn’s syndrome. Postgrad. Med. J. 75, 235–236 (1999)PubMed

87.

P. Mulatero, C. Bertello, N. Sukor, R. Gordon, D. Rossato, N. Daunt, D. Leggett, G. Mengozzi, F. Veglio, M. Stowasser, Impact of different diagnostic criteria during adrenal vein sampling on reproducibility of subtype diagnosis in patients with primary aldosteronism. Hypertension 55, 667–673 (2010)PubMedCrossRef

Title: Primary aldosteronism: from bench to bedside
Author: Norlela Sukor
Publication date: 01-02-2012
Publisher: Springer US
Published in: Endocrine / Issue 1/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-011-9553-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

A rare S33C mutation of CTNNB1 encoding β-catenin in a parathyroid adenoma found in an Italian primary hyperparathyroid cohort

Extrapituitary production of anterior pituitary hormones: an overview

Haplotype analysis of Apo AI-CIII-AIV gene cluster and lipids level: Tehran lipid and glucose study

Gitelman's syndrome: a pathophysiological and clinical update

New understanding and treatments for osteoporosis

Variable clinical presentation and outcome in pediatric patients with resistance to thyroid hormone (RTH)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials